Results
hypertension, SD, preeclampsia, seizures
ADVERSE EFFECTS, HEART DISEASE, PULMONARY EDEMA, ADVERSE EFFECTS, HYPERTENSION, HEART, HYPERTENSION, PREECLAMPSIA
Sixty-five pregnant females suffered from preeclampsia were eligible for enrollment during our study period. From them 5 patients were excluded (three patients refused to participate in the study, one patient had preexisting heart disease, and one patient showed inadequate temporal window). Thus, sixty consented singleton pregnant females who suffered preeclampsia with severe features were included and randomly allocated into two equal groups (Fig. 
Study flow diagramn = number of patients, IV = Intravenous, MgSO4 = Magnesium sulfate
Patients’ characteristics, preeclampsia severity features and laboratory results on admission of the studied groupsGroup M = Magnesium sulfate group, Group L = Labetalol group, n = Total number of subjects in each group, BMI = Body mass index, Pul.edema = pulmonary edema, Hb = hemoglobin, AST = aspartate aminotransferase, ALT = Alanine aminotransferase.*Hypertension as a severity feature was recorded if systolic blood pressure (SBP) ≥ 160 mmHg or diastolic blood pressure (DBP) ≥ 110 mmHg measured on two occasions at least 4 hours apart.Data were expressed as mean ± SD; number (percentage).Independent samples student’s t-test.P < 0.05 is significant.The middle cerebral artery TCD measurements including the MV, DIAS, PI as well as the calculated CPP and MCA velocity showed no statistically significant difference between both groups at all times of measurements (Table 
TCD measurements of the two studied groups at different timingsGroup M = Magnesium sulfate group, Group L = Labetalol group, n = Total number of subjects in each group, MV = Mean Velocity, DIAS = Mean End Diastolic Velocity, PI = Pulsatility Index, CPP = Cerebral Perfusion Pressure, MCA Velocity = Middle Cerebral Artery Velocity.Data were expressed as mean ± SD.Independent samples student’s t-test.P < 0.05 is significant.
TCD measurements at different timings within each groupGroup M = Magnesium sulfate group, Group L = Labetalol group, n = Total number of subjects in each group, MV = Mean Velocity, DIAS = Mean End Diastolic Velocity, PI = Pulsatility Index, CPP = Cerebral Perfusion Pressure, MCA Velocity = Middle Cerebral Artery Velocity.Data were expressed as mean ± SD.Repeated measure ANOVA testP < 0.05 is significant.* Both PI and CPP were statistically high significantly lower in both groups after 1 and 6 hours of drug administration compared to the baseline measurement.There was a statistically significant difference between the two studied groups regarding systolic, diastolic blood pressure, and heart rate after 1 hour of drug administration as it was found to be significantly higher among group M compared to group L with no statistically significant difference observed at other times of measurements between the two groups (Fig. 
Systolic blood pressure measurements at different timings between the studied groups. M group = Magnesium sulfate group, L group = Labetalol group
Diastolic blood pressure measurements at different timings between the studied groups. M group = Magnesium sulfate group, L group = Labetalol group
Heart rate measurements at different timings between the studied groupsM group = Magnesium sulfate group, L group = Labetalol group
Hemodynamic measurements at different timings within each groupGroup M = Magnesium sulfate group, Group L = Labetalol group, n = Total number of subjects in each group,, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, HR = Heart rate.Data were expressed as mean ± SD.Repeated measure ANOVA testP < 0.05 is significant.*SBP, DBP, and HR were significantly lower in both studied groups after 1 and 6 hours of drug administration compared to baseline readings.The persistence of hypertension and the need to add another antihypertensive drug with the studied medication was statistically significantly higher in the magnesium group compared to the labetalol group with the other adverse effects showed no statistically significant difference in both groups. No statistically significant difference was found between both groups regarding seizures occurrence, seizures occurred in 7 cases in the labetalol group versus 4 cases in magnesium groups (p-value = 0.317) (Table 
Adverse effects of the two studied drugs in both groupsGroup M = Magnesium sulfate group, Group L = Labetalol group, n = Total number of subjects in each group.Data were expressed as numbers (percentage).Independent samples student’s t-test.P < 0.05 is significant.* Persistence of hypertension and the need for another antihypertensive drug were highly significantly lower in the labetalol group.